EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus

Kefeng Sun, Siobhan Hayes, Colm Farrell, Ivy H Song

CPT: Pharmacometrics & Systems Pharmacology · 2023

DOI: 10.1002/psp4.12943 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2023. Verfasst von Kefeng Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Ribonucleosides. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Maribavir was approved by the US Food and Drug Administration for the treatment of patients aged ≥12 years and weighing ≥35 kg with posttransplant cytomegalovirus infection/disease refractory (with/without resistance) to valganciclovir, ganciclovir, cidofovir, or foscarnet, with an oral dose of 400 mg twice daily. With no pediatric clinical data available and difficulty in trial recruitment, population pharmacokinetic modeling and simulations were conducted to predict the pharmacokinetics and inform maribavir dosing in adolescents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsRibonucleosidesUnited StatesHumansAdolescentCytomegalovirusAntiviral AgentsGanciclovirBenzimidazolesDichlororibofuranosylbenzimidazole

Substanzen

Antiviral AgentsGanciclovirBenzimidazolesRibonucleosidesmaribavirDichlororibofuranosylbenzimidazole

Autor:innen und Institutionen

  • Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
  • ICON plc, Reading, UK.

Zitieren

APA

Sun, K., Hayes, S., Farrell, C., & Song, I. H. (2023). Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.12943

Vancouver

Sun K, Hayes S, Farrell C, Song IH. Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus. CPT: Pharmacometrics & Systems Pharmacology. 2023. doi:10.1002/psp4.12943

BibTeX
@article{Sun2023,
  author = {Sun, Kefeng and Hayes, Siobhan and Farrell, Colm and Song, Ivy H},
  title = {Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2023},
  doi = {10.1002/psp4.12943}
}
Kostenlos starten →